Similarly, preclinical data support that MCT1 inhibitors selectively inhibit tumor growth but spare the functional status of CD4+/CD8+ T cells and potentiate the synergistic effects of targeting tumor cells and regulating the TIME [233]. This evidence concerns the gene CD8A and neoplasm.